In the past week, LFST stock has gone down by -5.88%, with a monthly decline of -4.27% and a quarterly plunge of -18.25%. The volatility ratio for the week is 1.50%, and the volatility levels for the last 30 days are 2.72% for LifeStance Health Group Inc. The simple moving average for the past 20 days is -3.90% for LFST’s stock, with a -20.04% simple moving average for the past 200 days.
Is It Worth Investing in LifeStance Health Group Inc (NASDAQ: LFST) Right Now?
The 36-month beta value for LFST is also noteworthy at 1.22. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for LFST is 116.84M, and at present, short sellers hold a 7.84% of that float. The average trading volume of LFST on June 12, 2025 was 1.86M shares.
LFST) stock’s latest price update
LifeStance Health Group Inc (NASDAQ: LFST)’s stock price has gone decline by -2.10 in comparison to its previous close of 5.72, however, the company has experienced a -5.88% decrease in its stock price over the last five trading days. zacks.com reported 2025-06-05 that The consensus price target hints at a 45% upside potential for LifeStance Health (LFST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Analysts’ Opinion of LFST
Many brokerage firms have already submitted their reports for LFST stocks, with UBS repeating the rating for LFST by listing it as a “Buy.” The predicted price for LFST in the upcoming period, according to UBS is $8.50 based on the research report published on May 27, 2025 of the current year 2025.
KeyBanc Capital Markets, on the other hand, stated in their research note that they expect to see LFST reach a price target of $9. The rating they have provided for LFST stocks is “Overweight” according to the report published on April 08th, 2025.
Canaccord Genuity gave a rating of “Buy” to LFST, setting the target price at $8 in the report published on April 03rd of the current year.
LFST Trading at -9.80% from the 50-Day Moving Average
After a stumble in the market that brought LFST to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -34.96% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at LFST starting from Ramtekkar Ujjwal, who sale 16,000 shares at the price of $5.94 back on Jun 05 ’25. After this action, Ramtekkar Ujjwal now owns 113,435 shares of LifeStance Health Group Inc, valued at $95,040 using the latest closing price.
Ramtekkar Ujjwal, the Officer of LifeStance Health Group Inc, proposed sale 16,000 shares at $5.94 during a trade that took place back on Jun 05 ’25, which means that Ramtekkar Ujjwal is holding shares at $94,961 based on the most recent closing price.
Stock Fundamentals for LFST
Current profitability levels for the company are sitting at:
- -0.01 for the present operating margin
- 0.3 for the gross margin
The net margin for LifeStance Health Group Inc stands at -0.03. The total capital return value is set at -0.01. Equity return is now at value -2.47, with -1.69 for asset returns.
Based on LifeStance Health Group Inc (LFST), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at 0.64. The debt to equity ratio resting at 0.13. The interest coverage ratio of the stock is -0.54.
Currently, EBITDA for the company is 39.87 million with net debt to EBITDA at 1.51. When we switch over and look at the enterprise to sales, we see a ratio of 1.75. The receivables turnover for the company is 9.14for trailing twelve months and the total asset turnover is 0.61. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.47.
Conclusion
In summary, LifeStance Health Group Inc (LFST) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
